Liposome Co likes its trajectory

Although investors ignored positive data from three Phase III trials of The Liposome Co. Inc.'s Evacet liposomal formulation of doxorubicin to treat metastatic breast cancer, the company is looking at an eventful year end that should include a profitable fourth quarter as well as an NDA filing for Evacet.

The company's first product, Abelcet amphotericin B lipid complex to treat

Read the full 595 word article

How to gain access

Continue reading with a
two-week free trial.